で公開中です！ 詳しく見る
GILDのアイコン

Gilead Sciences
GILD

156.19 USD
-1.18
0.75%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
156.84
+0.65
0.42%
1日
-0.75%
5日間
2.86%
1か月
5.76%
3か月
14.59%
6か月
12.73%
年初来
28.45%
1年
32.53%
5年間
137.01%
10年間
115.02%
 

概要： Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

従業員数： 17,000

ヘルスケア 医薬品メーカー（総合）

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 55.6%
ニュートラル 37%
ネガティブ 7.4%
ニュートラル
Zacks Investment Research
昨日
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
ニュートラル
Business Wire
昨日
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for o.
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
ポジティブ
Zacks Investment Research
昨日
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
ポジティブ
Market Watch
昨日
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
ポジティブ
Schwab Network
昨日
The Big 3: MRK, GILD, XOM
The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a stabilizing healthcare sector, Gilead Sciences (GILD) as a stock "poised to continue upward price action," and Exxon Mobil (XOM) as a high-liquid name in a booming energy trade.
The Big 3: MRK, GILD, XOM
ポジティブ
Zacks Investment Research
昨日
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
ポジティブ
Benzinga
一昨日
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
ポジティブ
24/7 Wall Street
一昨日
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
ニュートラル
Zacks Investment Research
7 日前
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
ネガティブ
Zacks Investment Research
14 日前
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています